Explore this article's sources with AI
Follow PeptideMethods on Google
GLP-1 Drugs and Bone Density Review
A 2026 review found GLP-1 bone evidence too sparse for a class verdict, while small semaglutide and liraglutide trials raised questions.
Why we wrote this. Bone-loss claims can outrun small trials. We separate the new review's signal from what it cannot establish.
In this article (5 sections)
A systematic review published on 23 October 2026 found too little randomized evidence to determine how GLP-1 receptor agonists affect bone health in adults with overweight or obesity. The authors found eight trials with 493 participants, covering semaglutide, liraglutide, dulaglutide, and exenatide. They did not pool the results because the medicines and their weight-loss effects differed too much for a useful class average[1].
The review does raise a specific concern. The trials with the largest weight losses, one testing semaglutide and one testing liraglutide 3.0 mg, both reported lower bone mineral density at the lumbar spine. That pattern deserves better trials, but it does not establish that GLP-1 medicines cause osteoporosis or fractures[1].
What the review found
The researchers searched four databases for randomized trials lasting at least 12 weeks. Eligible studies enrolled adults whose mean baseline body mass index was above 25 and measured bone mineral density with dual-energy X-ray absorptiometry, usually shortened to DXA. DXA estimates how much mineral is present in bone at sites such as the hip and spine. Five trials enrolled people with type 2 diabetes, while three enrolled adults without diabetes[1].
Evidence was uneven. The review found one semaglutide trial, two liraglutide trials, one dulaglutide trial, and five exenatide trials. One study contributed more than one treatment comparison. Only three trials were judged at low risk of bias, and no medicine had more than one low-risk trial behind it. The authors rated the certainty of evidence as very low for every agent[1].
Results also moved in different directions. The two liraglutide trials used different doses and populations. Exenatide findings ranged from an increase in lumbar-spine bone mineral density in one trial to an imprecise decrease in another. A single class-wide estimate would have hidden those differences, which is why the authors reported each medicine separately rather than performing a meta-analysis[1].
The semaglutide signal came from 64 people
The only semaglutide trial in the review randomized 64 adults with increased fracture risk to semaglutide 1.0 mg once weekly or placebo for 52 weeks. Participants had a mean age of 63 years, and 55 of the 64 were postmenopausal women. The trial administered a diabetes-range dose. Its primary outcome was a blood marker of bone formation, not fractures[2].
Semaglutide did not improve the primary bone-formation marker, P-PINP. Compared with placebo, it produced a 6.8 kg greater reduction in body weight and higher CTX, a blood marker of bone resorption. Bone mineral density was also lower at the lumbar spine and total hip after 52 weeks. The estimated treatment differences were -0.018 g/cm² at the spine and -0.020 g/cm² at the hip[2].
Those measurements describe changes in density and bone turnover within this small, higher-risk group. The trial did not show a difference at the femoral neck, and it was not large or long enough to test whether semaglutide changes fracture rates. The authors wrote that the higher bone resorption could be explained by the accompanying weight loss[2]. Readers can find the wider drug evidence and regulatory context on our semaglutide research page.
Exercise changed the liraglutide result
A separate trial helps explain why treatment context matters. After an eight-week low-calorie diet, 195 adults with obesity and without diabetes were assigned to exercise, liraglutide 3.0 mg, both interventions, or placebo for 52 weeks. The published bone analysis was prespecified, but it was a secondary analysis rather than the trial's original main outcome[3].
The combined exercise and liraglutide group lost the most weight, while bone mineral density at the hip and lumbar spine was not detectably different from placebo. Liraglutide alone produced lower density at both sites than exercise alone despite similar weight loss. The comparison suggests that weight loss, medicine choice, and exercise cannot be treated as interchangeable explanations for a bone-density result[3]. It does not prove that a particular exercise plan prevents fractures during GLP-1 therapy.
What this review does not show
Bone mineral density is clinically useful, but it is not the same outcome as a fracture. None of these results establishes a fracture effect for semaglutide or for the GLP-1 class. The review also cannot separate a direct drug effect from the skeletal effects of losing weight, changes in mechanical loading, or differences in diet and activity. Its authors therefore call for adequately powered trials that study each medicine separately and include fracture outcomes[1].
The findings are not a reason to stop a prescribed medicine without clinical advice. They are a reason for researchers to measure skeletal outcomes directly, especially in people who already have low bone density or other fracture risks. A clinician can place bone health alongside the medicine's approved indication, expected benefit, and a patient's existing risk factors.
What we don't yet know
The main gap is agent-specific fracture evidence. Larger trials need enough follow-up to count fractures, not only short-term changes on DXA or blood markers. They also need to represent men, younger adults, and people taking current weight-management doses. The present review found just one semaglutide trial and two liraglutide trials, with most included studies conducted in people with type 2 diabetes[1].
For now, the careful reading is narrow. Small trials have produced bone-density signals that merit follow-up, particularly when treatment causes substantial weight loss. The evidence remains too sparse to assign one skeletal effect to every GLP-1 receptor agonist or to predict an individual patient's fracture risk.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
Do GLP-1 medicines cause bone loss?
The review could not establish that. It found small and clinically different trials, with very-low-certainty evidence for every medicine assessed. Some trials reported lower bone mineral density, but the evidence does not support one class-wide conclusion.
Did the semaglutide trial measure fractures?
No. The 52-week trial measured bone-turnover markers and bone mineral density in 64 adults with increased fracture risk. It was not large or long enough to determine whether semaglutide changes fracture rates.
Can exercise protect bone during GLP-1 treatment?
One liraglutide trial found that combined exercise and liraglutide preserved hip and spine bone mineral density compared with placebo while producing the greatest weight loss. That single study does not establish a universal exercise prescription or prove fracture prevention.
Should I stop a GLP-1 medicine because of this review?
The review is not evidence for stopping treatment on your own. It identifies research gaps rather than a class-wide fracture risk. Discuss personal bone-health concerns and treatment decisions with the clinician managing your prescription.
Sources
- [1]Lai CH, Li YT, Wu TS, et al. Skeletal effects of GLP-1 receptor agonist therapy in adults with overweight or obesity: a systematic review. Arch Osteoporos. 2026;21:148. PMID 42920024.Tier 1 · primary↩
- [2]Hansen MS, Wölfel EM, Jeromdesella S, et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised phase 2 trial. EClinicalMedicine. 2024;72:102624. PMID 38737002.Tier 1 · primary↩
- [3]Jensen SBK, Sørensen V, Sandsdal RM, et al. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment. JAMA Netw Open. 2024;7:e2416775. PMID 38916894.Tier 1 · primary↩
No revisions yet. First published .